Dopamine Agonists: Core Growth Enabler in the The Rising Prevalence Of Neurological Disorders Fueling Growth In The Market Due To Increasing Cases Of Alzheimer's And Parkinson's Diseases Market, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Dopamine Agonists Industry Market Size Be by 2025?
Over the past few years, the size of the dopamine agonists market has seen substantial growth. It is projected to increase from a market value of $2.57 billion in 2024 to $2.73 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4%. Factors contributing to growth during the historic period include a surge in the number of Parkinson's disease cases, an escalation in diagnoses of restless legs syndrome (RLS), more comprehensive reimbursement coverage, an increase in funding for research into CNS disorders, and a heightened awareness surrounding healthcare.

What's the Long-Term Growth Forecast for the Dopamine Agonists Market Size Through 2029?
The market of dopamine agonists is predicted to experience robust growth in the upcoming years. The market is set to enlarge to "$3.61 billion in 2029 with a compound annual growth rate (CAGR) of 7.2%. The expansion in the projection period is linked to the increase in neurological disorders, the aging worldwide population, growth in exploratory and clinical trial efforts, the broadening of combination therapies, heightened awareness, and diagnosis rates. Key market trends for the forecast duration encompass personalized medicine along with genetic profiling, wearable technologies for drug delivery, the use of AI and machine learning in the creation of drugs, extended-release formulation approaches, and the application of nanotechnology in drug delivery.

View the full report here:
https://www.thebusinessresearchcompany.com/report/dopamine-agonists-global-market-report

What Are the Key Growth Drivers Fueling the Dopamine Agonists Market Expansion?
The dopamine agonist market is set to surge due to the escalating instances of neurological disorders. These disorders, which can result in movement, cognitive, or behaviour issues, are diseases that affect the brain, nerves or spine. Higher life expectancies partly contribute to the increased frequency of neurological disorders, as risk factors for conditions like Alzheimer's and Parkinson's are associated with aging. By activating dopamine receptors in the brain, dopamine agonists can help manage disorders like Parkinson's disease, providing better control and alleviation of symptoms. The Alzheimer's Disease Facts and Figures report, issued in 2024 by the Alzheimer's Association, a volunteer health organization in the US focusing on Alzheimer's disease support, research, and care, indicated that in 2022, Alzheimer's dementia was diagnosed in 6.5 million Americans aged 65 and above, with this number rising to 6.9 million in 2024. Hence, the growth of the dopamine agonist market will be fuelled by the growing incidence of neurological disorders.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23375&type=smp

What Are the Key Trends Driving Dopamine Agonists Market Growth?
Key players in the dopamine agonists market are prioritizing advancements like flexible-dose monotherapy, a method aimed at enhancing patient compliance, minimizing adverse effects, and providing individually tailored treatments for neurological conditions. This treatment technique employs a single, dosage-adjustable drug, enabling medical professionals to personalize the dose amount to the distinct needs and responses of each patient. For example, in November 2024, AbbVie Inc., a renowned biopharmaceutical organization based in the US, revealed optimistic preliminary results from its Phase 3 TEMPO-2 trial. The results showed that the experimental tavapadon - a flexible-dose monotherapy (administered once daily at 5-15 mg) - notably enhanced motor performance in early-stage Parkinson's disease patients. The trial accomplished its major objective with a significant decrease in the MDS-UPDRS Parts II and III scores, and achieved key secondary goals, indicating substantial progress in daily motor activities. Tavapadon represents the initial D1/D5 partial agonist under investigation for once-daily Parkinson's therapy.

How Is the Dopamine Agonists Market Segmented?
The dopamine agonists market covered in this report is segmented -

1) By Product Type: Ergot Based Dopamine Agonists, Non Ergot Based Dopamine Agonists
2) By Route of Administration: Oral, Parenteral, Transdermal Patches
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
4) By Application: Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia
5) By End User: Hospitals, Clinics, Home Care Settings

Subsegments:
1) Ergot-Based Dopamine Agonists: Bromocriptine, Cabergoline, Pergolide
2) Non-Ergot-Based Dopamine Agonists: Pramipexole, Ropinirole, Rotigotine, Apomorphine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23375&type=smp

Which Companies Are Leading the Charge in Dopamine Agonists Market Innovation?
Major companies operating in the dopamine agonists market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., UCB Pharma S.A., Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd., ACADIA Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd., Shodhana Laboratories Pvt. Ltd., Oceanic Pharmachem Pvt. Ltd., AffaMed Therapeutics Holdings Limited, Schwarz Pharma AG

Which Regions Are Leading the Global Dopamine Agonists Market in Revenue?
North America was the largest region in the dopamine agonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dopamine agonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23375

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.